Praxis Precision Medicines, Inc.
PRAX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$267.59
KIRA · Stoqly’s AI analyst, in plain words
- Praxis Precision Medicines, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Praxis Precision Medicines, Inc. lost $303M in fiscal 2025.
- Free cash flow was −$249M in fiscal 2025, — of revenue.
Market cap
$7.8B
P/E
—
Revenue
$0.0M
Net income
−$303M
Free cash flow
−$249M
Operating margin
—
Praxis Precision Medicines, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$303M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Praxis Precision Medicines, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- Praxis Precision Medicines, Inc.
- CIK
- 0001689548
Praxis Precision Medicines, Inc. · PRAX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $2.4M | $8.6M | $0.0M |
| Revenue growth | — | — | — | 249.5% | −100.0% |
| Operating margin | — | — | −5,164.4% | −2,340.3% | — |
| Net income | −$167M | −$214M | −$123M | −$183M | −$303M |
| Net margin | — | — | −5,037.9% | −2,137.5% | — |
| Diluted EPS | −$3.94 | −$69.65 | −$18.69 | −$10.21 | −$13.48 |
| Cash | |||||
| Cash from operations | −$125M | −$185M | −$111M | −$132M | −$249M |
| Capital expenditure | $1.1M | $0.4M | $0.1M | $0.0M | $0.1M |
| Free cash flow | −$126M | −$185M | −$111M | −$132M | −$249M |
| FCF margin | — | — | −4,543.8% | −1,540.5% | — |
| Share count change | 374.3% | −92.8% | 114.6% | 171.5% | 25.7% |
| Debt and strength | |||||
| Cash and short-term investments | $244M | $100M | $81.3M | $393M | $599M |
| Shareholders' equity | $251M | $76.1M | $69.7M | $445M | $878M |
| Current ratio | 7.5x | 3.2x | 5.4x | 10.8x | 10.2x |
| Returns and quality | |||||
| Return on equity | −62.1% | −130.9% | −169.1% | −71.0% | −45.8% |
| Return on tangible equity | −66.6% | −281.2% | −176.9% | −41.0% | −34.5% |
| Piotroski F-score | — | — | 4 | 3 | 2 |
| Altman Z'' | 4.5 | −21.2 | −24.7 | 9.0 | 13.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$11.1M
3 insiders
Of sales under plans
33%
$3.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Praxis Precision Medicines, Inc. · PRAX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $267.59 a share, the company is worth $7.8B.
Source: SEC EDGAR XBRL filings (CIK 0001689548). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.